5-(3,5-dimethoxy-benzylidene)-thiazolidine-2,4-dione | 924660-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3,5-dimethoxy-benzylidene)-thiazolidine-2,4-dione
• 英文别名: 5-(3,5-Dimethoxybenzylidene)thiazolidine-2,4-dione；(5Z)-5-[(3,5-dimethoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 924660-67-3
• 化学式: C₁₂H₁₁NO₄S
• 分子量: 265.29
• InChiKey: VRHTYBLWNKWMQB-YHYXMXQVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(3,5-dimethoxy-benzylidene)-thiazolidine-2,4-dione 、 靛红 、 DL-脯氨酸 以 1,4-二氧六环 、 水 为溶剂， 以42%的产率得到
  参考文献：
  名称：

  通过偶氮甲meth基的1,3-偶极环加成反应一锅合成新型双螺[氧吲哚-噻唑烷二酮/硫代-噻唑烷酮/二氢吡唑啉酮]-吡咯烷†

  摘要：

  通过偶氮甲啶内酯的区域和立体选择性1,3-偶极环加成反应合成了一系列新型的双螺并[oxindole-噻唑烷二酮]吡咯烷，双螺并[oxindole-thioxothiazolidinone]-吡咯烷，二螺[oxindole-dihydro-pyrazolone]吡咯烷。在单罐操作方案中由氨基酸和氨基酸酯与π缺失的烯烃生成的高收率。X射线晶体学研究在4a和5a中确定了螺-羟吲哚和螺-噻唑烷二酮环之间的正交排列。

  DOI：

  10.1002/jhet.5570430631

文献信息

• Novel heterocyclic analogs of diphenylethylene compounds
  申请人：——

  公开号：US20020032225A1

  公开（公告）日：2002-03-14

  Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

  提供含有噻唑烷二酮或噁唑烷二酮基团的新型二苯乙烯化合物及其衍生物，能有效降低II型糖尿病动物模型中的血糖水平、血清胰岛素、甘油三酯和游离脂肪酸水平。与先前报道的已知能降低瘦素水平的噻唑烷二酮化合物相比，这些新化合物能增加瘦素水平，并且没有已知的肝毒性。这些化合物被披露为用于各种治疗，包括治疗炎症、炎症和免疫性疾病、胰岛素抵抗、高脂血症、冠状动脉疾病、癌症和多发性硬化等。
• NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS
  申请人：Calyx Therapeutics, Inc.

  公开号：EP1360178A2

  公开（公告）日：2003-11-12
• US7105552B2
  申请人：——

  公开号：US7105552B2

  公开（公告）日：2006-09-12
• US7202366B2
  申请人：——

  公开号：US7202366B2

  公开（公告）日：2007-04-10
• [EN] NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS<br/>[FR] NOUVEAUX ANALOGUES HETEROCYCLIQUES DE COMPOSES DE DIPHENYLETHYLENE
  申请人：CALYX THERAPEUTICS INC

  公开号：WO2001095859A2

  公开（公告）日：2001-12-20

  Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.